Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...

About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 pivotal clinical trial evaluating IO102-IO103 in ...

“We have already adopted the strategy of a checkpoint inhibitor [pembrolizumab] after chemoradiation for stage ... tertiary ...

This investigator-initiated, single-arm, open-label, phase 2 study evaluates the efficacy and safety of a triple combination regimen of pembrolizumab plus plinabulin/docetaxel. The study intends to ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Data from an open-label multi-cohort Phase 1/2 clinical trial (NCT05918445 ... clinical trial evaluating BNT316/ONC-392 in combination with pembrolizumab in patients with platinum-resistant ovarian ...

Welcome to the NovoCure Q3 2024 earnings conference call. [Operator instructions] Please be advised that today's conference ...

LUNAR-4 is setting treatment with Tumor Treating Fields therapy in pembrolizumab in the second ... written for patients that fit your label. I know this is going to build over time, but maybe ...